NCT02859012View on ClinicalTrials.gov

Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

August 31, 2020

Conditions
Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions
DRUG

Axitinib

Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)

OTHER

Observation

this group is observational ones.

Trial Locations (1)

110-744

Department of Internal Medicine, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02859012 - Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma | Biotech Hunter | Biotech Hunter